In a randomised, placebo controlled, double blind study inosine pranobex was assessed as a possible second line drug in rheumatoid arthritis. Twenty four patients received inosine pranobex (3 g/day) and 26 patients received placebo for up to 24 weeks. Morning stiffness, articular index, grip strength, pain score, erythrocyte sedimentation rate, C reactive protein, IgG, IgM, and serum urate were assessed at weeks 0, 12, and 24. Baseline characteristics were similar except for a significantly higher C reactive protein in the placebo group. No significant improvement occurred in any variable: (a) when comparing week 0 with week 12 or week 24 for either group, (b) comparing active drug with placebo at week 12 or 24, or (c) taking all 50 patients as one group. Withdrawal from the study for lack of response or side effects was similar in both groups. Serum urate increased transiently but significantly with inosine pranobex (a recognised side effect). It is concluded that inosine pranobex has no second line activity in rheumatoid arthritis. Further, 50 patients effectively given placebo showed no spontaneous improvement in their disease activity.
Inosine pranobex is a synthetic immunomodulating drug.' It is the p-acetamidobenzoic acid salt of the N N-dimethylamino-2-propanol: inosine complex in a 3:1 molar ratio, and is also known as isoprinosine, inosiplex, and methisoprinol. It increases interleukin 2 production by lymphocytes,2 stimulates T cell differentiation,3 and induces lymphocyte surface markers. 3 Inosine pranobex has been used in various viral illnesses4-for example, it speeds recovery from herpes simplex infections5 and may prolong survival in subacute sclerosing panencephalitis,6 a disorder of some interest given current speculation about a potential viral aetiology for rheumatoid arthritis (RA) .
A previous small open study of 
Results
Twenty four patients were assigned to active drug and 26 to placebo. Table 1 shows their baseline characteristics. The only significant difference between the groups was a higher C reactive protein in the placebo group (p=002).
TOXICITY
Eleven of 24 patients treated with inosine pranobex withdrew before the end of the study as did 14 of 26 placebo treated patients. Table 2 shows the reasons for withdrawal and the adverse effects not severe enough to lead to withdrawal. Overall in the inosine pranobex group serum urate concentrations rose significandy at week 12 (median 240 imol/l at week 0, 320 iumol/l at week 12, p=0 001) but were falling by week 24 (median 295 nmolJl, p=0 025 compared with week 0) (table 3). The slight rise in the placebo group was not significant (table  3) . In six patients taking inosine pranobex serum urate rose well above normal (mean week AlIt 13 (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) 14-5 (6-3-19) EMSt (h) improved with reduction of early morning stiffness, joint circumference, ESR, and fibrinogen. 7 Close inspection of the data shows that changes in these indices were often too small to be clinically meaningful, and only three out of 15 could truly be said to have benefited. A German study used a complex protocol with intravenous corticosteroids for some patients, and many were receiving oral corticosteroids as well. 8 As rheumatologists have few minimally toxic drugs the suggestion of possible benefit warranted further investigation of inosine pranobex.
Although originally labelled an antiviral drug, inosine pranobex is more correctly designated an immunomodulating agent. 1 It is used against a variety of viral diseases, including herpes simplex5 influenza (where it partially restores the immunosuppression associated with infection),9 and subacute sclerosing panencephalitis.6 Given early in infectious mononucleosis inosine pranobex produces no worthwhile clinical benefit as shown in a detailed but unpublished paper (Gillett). A small study showed that inosine pranobex augmented proliferation of B cells containing Epstein-Barr virus nuclear material, both from patients with infectious mononucleosis and those with RA. 10 Inosine pranobex also increases interleukin 2 production by lymphocytes in vitro.2 Whether one would theoretically expect these effects to be beneficial in RA is debatable, though it is worth noting that cyclosporin A reduces interleukin 2 production. Perhaps inosine pranobex should be given earlier in the disease, when any aetiological agent might still be present.
When all 50 patients are taken as a group, effectively though unintentionally given placebo, it is clear that active RA of this severity does not show spontaneous remission. This contrasts with a recent study in the United States, where the placebo group showed considerable improvement. 1 
